Wanbury Ltd
- Market Cap ₹ 232 Cr.
- Current Price ₹ 71.8
- High / Low ₹ 72.6 / 33.0
- Stock P/E 109
- Book Value ₹ -10.0
- Dividend Yield 0.00 %
- ROCE 20.8 %
- ROE %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 6.19% over past five years.
- Promoter holding is low: 39.8%
- Contingent liabilities of Rs.907 Cr.
- Promoters have pledged 76.7% of their holding.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -12.3%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
386 | 459 | 661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 500 | 529 | |
388 | 491 | 637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 476 | 489 | |
Operating Profit | -2 | -32 | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 23 | 40 |
OPM % | -1% | -7% | 4% | 9% | 8% | 4% | -18% | 4% | 6% | 5% | 7% | 5% | 7% |
21 | 5 | -78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | 0 | -1 | |
Interest | 40 | 37 | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 24 |
Depreciation | 17 | 23 | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 |
Profit before tax | -39 | -87 | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 2 |
Tax % | 0% | -0% | -2% | 28% | 0% | 1% | 1% | 1% | 0% | -2% | -0% | -1% | |
-39 | -87 | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 2 | |
EPS in Rs | -22.38 | -50.19 | -63.95 | 1.60 | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 0.47 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 6% |
3 Years: | 11% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 11% |
3 Years: | 13% |
TTM: | 266% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 29% |
3 Years: | 29% |
1 Year: | 6% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
17 | 17 | 20 | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | |
Reserves | 27 | -65 | -212 | -214 | -209 | -176 | -208 | -233 | -168 | -181 | -56 | -66 |
455 | 415 | 389 | 381 | 362 | 300 | 250 | 260 | 190 | 192 | 100 | 68 | |
309 | 406 | 209 | 209 | 215 | 265 | 207 | 236 | 232 | 253 | 276 | 268 | |
Total Liabilities | 809 | 773 | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 |
439 | 423 | 174 | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | |
CWIP | 17 | 25 | 13 | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 |
Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
352 | 324 | 219 | 213 | 193 | 216 | 84 | 105 | 101 | 111 | 183 | 135 | |
Total Assets | 809 | 773 | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 87 | 68 | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | |
-32 | -21 | -6 | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | |
24 | -64 | -71 | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | |
Net Cash Flow | 2 | 3 | -9 | 5 | -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 107 | 67 | 57 | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 50 |
Inventory Days | 113 | 63 | 42 | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 27 |
Days Payable | 159 | 114 | 113 | 301 | 172 | 260 | 174 | 209 | 253 | 221 | 233 | 179 |
Cash Conversion Cycle | 61 | 15 | -14 | -55 | -38 | -125 | -118 | -131 | -177 | -148 | -128 | -103 |
Working Capital Days | -165 | -159 | -3 | -26 | -45 | -132 | -195 | -175 | -212 | -168 | -103 | -100 |
ROCE % | -1% | -11% | 4% | 12% | 57% | -1% | 26% | 31% | 27% | 46% | 21% |
Documents
Announcements
- Closure of Trading Window 29 Sep
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 27 Sep
- Shareholder Meeting / Postal Ballot-Outcome of AGM 27 Sep
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Sep
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Sep - Newspaper clipping - Information regarding Annual General Meeting to be held through VC / OAVM.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio
The company has two divisions API & Formulations.
APIs: The company has 13 products under its API segment which includes Metformin, Tramadol, Sertraline, Diphenhydramine Hcl, mefenamic acid, Promethazine, and others. It is also the largest manufacturer of Metformin with a capacity of 8,500 TPA.
Formulations: It sells ~70 products under various brands under this segment such as antibiotics, antiulcerants, pain management, neuropathic pain management, protein supplements, laxative, antiallergen, constipation, calcium supplement, and others. [1] [2]